– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials –
– Series A Financing led by the Perceptive Xontogeny Venture Fund –
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).
The proceeds from the financing will fund Phase 1 and ...
Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales
SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic ...
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.
The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) ...
Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ...
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes (T2D). Zucara Therapeutics will match the funding with an additional $85,000 in cash and in-kind contributions, including scientific ...
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ...
Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust.
As part of the agreement, Helmsley will provide the funding to support preclinical advancement of Zucara’s lead drug candidate. The partnership is structured as a program-related investment (PRI) in the form of a loan to Zucara.
Zucara recently defined its lead drug candidate ...
VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note.
Zucara recently defined its lead drug candidate, ZT-01, and ...
TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE).
Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target.
Nacellins are a type of peptide macrocycle that can often exhibit ...